Insider Selling: Tabula Rasa HealthCare Inc (NASDAQ:TRHC) Director Sells $52,600.00 in Stock

Share on StockTwits

Tabula Rasa HealthCare Inc (NASDAQ:TRHC) Director Gordon Tunstall sold 1,000 shares of the business’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $52.60, for a total transaction of $52,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Gordon Tunstall also recently made the following trade(s):

  • On Wednesday, June 19th, Gordon Tunstall sold 1,000 shares of Tabula Rasa HealthCare stock. The shares were sold at an average price of $51.52, for a total transaction of $51,520.00.

TRHC opened at $54.25 on Friday. Tabula Rasa HealthCare Inc has a 1-year low of $40.86 and a 1-year high of $91.16. The company has a current ratio of 1.80, a quick ratio of 1.73 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $1.19 billion, a P/E ratio of 159.56 and a beta of 1.62. The firm has a fifty day moving average of $48.02.

Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.14) earnings per share for the quarter, meeting the consensus estimate of ($0.14). Tabula Rasa HealthCare had a negative net margin of 18.15% and a positive return on equity of 4.22%. The firm had revenue of $60.96 million during the quarter, compared to the consensus estimate of $59.24 million. As a group, analysts forecast that Tabula Rasa HealthCare Inc will post -0.55 earnings per share for the current fiscal year.

Several equities research analysts have weighed in on TRHC shares. Piper Jaffray Companies lifted their price target on shares of Beigene to $180.00 and gave the company an “overweight” rating in a research note on Thursday, May 9th. Cantor Fitzgerald started coverage on shares of CytomX Therapeutics in a research note on Monday, May 13th. They issued an “overweight” rating and a $21.00 price target for the company. Guggenheim started coverage on shares of Patterson Companies in a research note on Wednesday, April 17th. They issued a “neutral” rating and a $23.00 price target for the company. Zacks Investment Research raised shares of Vistra Energy from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research note on Saturday. Finally, TheStreet downgraded shares of Twin Disc from a “b-” rating to a “c+” rating in a research note on Tuesday, June 11th. Three equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $82.12.

Large investors have recently bought and sold shares of the company. First Mercantile Trust Co. increased its position in shares of Tabula Rasa HealthCare by 64.5% during the first quarter. First Mercantile Trust Co. now owns 995 shares of the company’s stock worth $56,000 after acquiring an additional 390 shares in the last quarter. South Dakota Investment Council bought a new stake in shares of Tabula Rasa HealthCare during the first quarter worth about $141,000. Belpointe Asset Management LLC bought a new stake in shares of Tabula Rasa HealthCare during the first quarter worth about $172,000. LS Investment Advisors LLC increased its position in shares of Tabula Rasa HealthCare by 11.2% during the first quarter. LS Investment Advisors LLC now owns 3,129 shares of the company’s stock worth $177,000 after acquiring an additional 316 shares in the last quarter. Finally, NumerixS Investment Technologies Inc bought a new stake in shares of Tabula Rasa HealthCare during the first quarter worth about $212,000. 86.68% of the stock is owned by institutional investors.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Featured Article: Forex

Insider Buying and Selling by Quarter for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply